

## References

1. Byc' JuV, Pishak VP, Ataman AV. Kyiv–Chernovtsy, 1999.330p.
2. Talaeva T.V., Bratus' V.V. *Ukrains'kij kardiologichnij zhurnal – Ukr J Cardiol* 2001;6:69–74.
3. Alexopoulos N, Raggi P. Calcification in atherosclerosis. *Nature Rev* 2009;6:681–8.
4. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. *Clin Immunol* 2010;134:33–46.
5. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNF- $\alpha$  therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. *Am J Hypertens* 2012;25:644–50.
6. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor a therapy and cardiovascular events in rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2011;63:522–9.
7. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, Curtiss LK, Corr M, Witztum JL. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. *J Clin Invest* 2004;114:427–37.
8. Blaha MJ, Rivera JJ, Budoff MJ, Blankstein R, Agatston A, O'Leary DH, Cushman M, Lakoski S, Criqui MH, Szklo M, Blumenthal RS, Nasir K. Association between obesity, high-sensitivity C-reactive protein > 2 mg/L, and subclinical atherosclerosis. *Arterioscler Thromb Vasc Biol* 2011;31:1430–8.
9. van Breukelen, van der Stoep DF, Klop B, van Zeben D, Hazes JM, Castro Cabezas M. Cardiovascular risk in rheumatoid arthritis: How to lower the risk? *Atherosclerosis* 2013;213:163–72.
10. Bulgarelli A, Martins DAA, Caramelli B, Maranhão RC. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. *J Cardiovasc Pharmacol* 2012;59:308–14.
11. Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, Mandet C, Kohler HV, Kaveri SV, Nicoletti A. *J Am Coll Cardiol* 2007;50:540–6.
12. Chatterjee Adhikari M, Guin A, Chakraborty S, Sinhamahapatra P, Ghosh A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. *Semin Arthritis Rheum* 2012;41:669–75.
13. Colussi G-L, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. *Diabetes Care* 2007;30:2349–54.
14. Cooper S.A, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, Stas S, Sowers JR. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. *JP – Heart* 2007;293:H2009–H2023.
15. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional cardiac risk factors. *Arthritis Rheum* 2001;44:2737–45.

16. Engelbertsen D, Andersson L, Ljungcrantz I, Wigren M, Hedblad B, Nilsson J, Björkbacka H. T-Helper 2 Immunity Is Associated With Reduced Risk of Myocardial Infarction and Stroke. *Arterioscler Thromb Vasc Biol* 2013;33:637–44.
17. Ferrante A, Giardina AR, Ciccia F, Parrinello G, Licata G, Avellone G, Giardina E, Impastato R, Triolo G. Long-term anti-tumor necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis. *Rheumatol Int* 2009;30:193–8.
18. Gao Q, Jiang Y, Ma T, Zhu F, Gao F, Zhang P, Guo C, Wang Q, Wang X, Ma C, Zhang Y, Chen W, Zhang L. A Critical Function of Th17 Proinflammatory Cells in the Development of Atherosclerotic Plaque in Mice. *J Immunol* 2010;185:5820–7.
19. Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G, Marchesi S, Pirro M, Ragni F, Shoenfeld Y, Mannarino E. CD4<sup>+</sup>CD28<sup>-</sup> T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. *Circulation* 2004;109:2744–8.
20. Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. *Arthritis Res Ther* 2008;10:213.
21. Hamirani YS, Pandey S, Rivera JJ, Ndumele C, Budoff MJ, Blumenthal RS, Nasir K. Markers of inflammation and coronary artery calcification: a systematic review. *Atherosclerosis* 2008;201:1–7.
22. Hansson GK, Nilsson J. Vaccination against atherosclerosis? Induction of atheroprotective immunity. *Semin Immunopathol* 2009;31:95–101.
23. Hart F.W. Rheumatoid arthritis: extra-articular manifestations. Part II. *Br Med J* 1970;II:747–52.
24. Hazen S.L. Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity. *J Biol Chem* 2008;283:15527–31.
25. Herbin O, Ait-Oufella H, Yu W, Fredrikson GN, Aubier B, Perez N, Barateau V, Nilsson J, Tedgui A, Mallat Z. Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice. *Arterioscler Thromb Vasc Biol* 2012;32:605–12.
26. Hudgins LC, Parker TS, Levine DM, Gordon BR, Saal SD, Jiang XC, Seidman CE, Tremaroli JD, Lai J, Rubin AL. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. *J Lipid Res* 2003;44:1489–98.
27. Iwakiri T, Yano Y, Sato Y, Hatakeyama K, Marutsuka K, Fujimoto S, Kitamura K, Kario K, Asada Y. Usefulness of carotid intima-media thickness measurement as an indicator of generalized atherosclerosis: Findings from autopsy analysis. *Atherosclerosis* 2012;224:359–62.
28. Iwamoto Y, Maruhashi T, Yuichi Fujii, Idei N, Fujimura N, Mikami S, Kajikawa M, Matsumoto T, Kihara Y, Chayama K, Noma K, Nakashima A, Higashi Y. Intima-Media Thickness of Brachial Artery, Vascular Function, and Cardiovascular Risk Factors. *Arterioscler Thromb Vasc Biol* 2012;32:2295–303.
29. Jenny NS, Brown ER, Detrano R, Folsom AR, Saad MF, Shea S, Szklo M, Herrington DM, Jacobs DR. Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis* 2010;209:226–9.

30. Kawashiri SY, Kawakami A, Yamasaki S, Imazato T, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Nakamura H, Ida H, Origuchi T, Ueki Y, Eguchi K. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. *Rheumatol Int* 2011;31:451–6.
31. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. *Lipid Res* 2004;45:1169–96.
32. Kim JA, Jang HJ, Martinez-Lemus LA, Sowers JR. Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. *Am J Physiol Endocrinol Metab* 2012;302:E201–E208.
33. Kitchens RL, Thompson PA, Munford RS, O'Keefe GE. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. *J Lipid Res* 2003;44:2339–48.
34. Klingenberg R, Lebens M, Hermansson A. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. *Arterioscler Thromb Vasc Biol* 2010;30:946–52.
35. Knowlton N, Wages JA, Centola MB, Alaupovic P. Apolipoprotein-defined lipoprotein abnormalities in rheumatoid arthritis patients and their potential impact on cardiovascular disease. *Scand J Rheumatol* 2012;41:165–9.
36. Leonarduzzi G, Gamba P, Gargiulo S, Biasi F, Poli G. Inflammation-related gene expression by lipid oxidation-derived products in the progression of atherosclerosis. *Free Radic Biol Med* 2012;52:19–34.
37. Lieb W, Larson M, Benjamin EJ, Yin X, Tofler GH, Selhub J, Jacques PF, Wang TJ, Vita JA, Levy D, Vasan RS, Mitchell GF. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study. *Circulation* 2009;119:37–43.
38. Lopes-Virella M.F., Hunt K.J., Baker N.L. Lachin J, Nathan DM, Virella G. Levels of Oxidized LDL and Advanced Glycation End Products–Modified LDL in Circulating Immune Complexes Are Strongly Associated With Increased Levels of Carotid Intima-Media Thickness and Its Progression in Type 1 Diabetes. *Diabetes* 2011;60:582–9.
39. Lu X, Xia M, Endresz V, Faludi I, Mundkur L, Gonczol E, Chen D, Kakkar VV. Immunization With a Combination of 2 Peptides Derived From the C5a Receptor Significantly Reduces Early Atherosclerotic Lesion in Ldlrtm1HerApobtm2Sgy J Mice. *Arterioscler Thromb Vasc Biol* 2012;32:2358–71.
40. Madan M, Bishayi B, Hoge M, Amar S. Atheroprotective role of interleukin-6 in diet- and/or pathogen-associated atherosclerosis using an ApoE heterozygote murine model. *Atherosclerosis* 2008;197:504–14.
41. Mäki-Petäjä KM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW, Harish S, Furlong A, McEniery CM, Brown J, Wilkinson IB. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. *Circulation* 2006;114:1185–92.
42. Maradit-Kremers H, Nicola PJ, Crowson CS, Ilman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2005;52:722–32.

43. Marder W, Khalatbari S, Myles JD, Hench R, Yalavarthi S, Lustig S, Brook R, Kaplan MJ. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. *Ann Rheum Dis* 2011;70:1550–5.
44. McMahon M, Grossman J, Fitzgerald J, Dahlin-Lee E, Wallace DJ, Thong BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman AM, Hahn BH. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. *Arthritis Rheum* 2006;54:2541–9.
45. Michaelsen TE, Sandlie I, Bratlie DB, Sandin RH, Ihle O. Structural difference in the complement activation site of human IgG1 and IgG3. *Scand J Immunol* 2009;70:553–64.
46. Mizia-Stec K, Zahorska-Markiewicz B, Manddecki T. Hyperlipidemia and serum cytokines in patients with coronary heart disease. *Acta Cardiol* 2003;58(1):9–15.
47. Moreau KL, Deane KD, Meditz AL, Kohrt WM. Tumor necrosis factor- $\alpha$  inhibition improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women. *Atherosclerosis* 2013;230:390–6.
48. Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. *Ann Rheum Dis* 2011;70:482–7.
49. Nambi V, Chambless L, He M, Folsom AR, Mosley T, Boerwinkle E, Ballantyne CM. Common carotid artery intima–media thickness is as good as carotid intima–media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. *Eur Heart J* 2012;33:183–90.
50. Nyssönen K, Kurl S, Karppi J. LDL oxidative modification and carotid atherosclerosis: Results of a multicenter study. *Atherosclerosis* 2012;225:231–6.
51. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. *Proc Natl Acad Sci USA* 1995;92:821–5.
52. Parra S, Vives G, Ferré R, González M, Guardiola M, Ribalta J, Castro A. Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients. *Atherosclerosis* 2012;225:224–30.
53. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitis G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. *Ann Rheum Dis* 2010;69:325–31.
54. Rauchhaus M, Clark A.L, Doehner W, Davos C, Bolger A, Sharma R, Coats AJ, Anker SD. The relationship between cholesterol and survival in patients with chronic heart failure. *JACC* 2003;42:1933–40.
55. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008;359:2195–207.

56. Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. *J Lipid Res* 2006;47:1975–83.
57. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D, Rendon A, Nelson CP, Braund PS, Hall AS, Chasman DI, Tybjærg-Hansen A, Chambers JC, Benjamin EJ, Franks PW, Clarke R, Wilde AA, Trip MD, Steri M, Wittteman JC, Qi L, van der Schoot CE, de Faire U, Erdmann J, Stringham HM, Koenig W, Rader DJ, Melzer D, Reich D, Psaty BM, Kleber ME, Panagiotakos DB, Willeit J, Wennberg P, Woodward M, Adamovic S, Rimm EB, Meade TW, Gillum RF, Shaffer JA, Hofman A, Onat A, Sundström J, Wassertheil-Smoller S, Mellström D, Gallacher J, Cushman M, Tracy RP, Kauhanen J, Karlsson M, Salonen JT, Wilhelmsen L, Amouyel P, Cantin B, Best LG, Ben-Shlomo Y, Manson JE, Davey-Smith G, de Bakker PI, O'Donnell CJ, Wilson JF, Wilson AG, Assimes TL, Jansson JO, Ohlsson C, Tivesten Å, Ljunggren Ö, Reilly MP, Hamsten A, Ingelsson E, Cambien F, Hung J, Thomas GN, Boehnke M, Schunkert H, Asselbergs FW, Kastelein JJ, Gudnason V, Salomaa V, Harris TB, Kooner JS, Allin KH, Nordestgaard BG, Hopewell JC, Goodall AH, Ridker PM, Hólm H, Watkins H, Ouwehand WH, Samani NJ, Kaptoge S, Di Angelantonio E, Harari O, Danesh J. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. *Lancet* 2012;379:1205–13.
58. Sattar N, McCarey DW, Capell H, Innes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. *Circulation* 2003;108:2957–63.
59. Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A, Bavendiek U, von Felden J, Divchev D, Kempf T, Wollert KC, Seegert D, Rose-John S, Tietge UJ, Schieffer B, Grote K. Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice. *Arterioscler.Thromb.Vasc.Biol.* 2012;32:281–290.
60. Semb AG, Rollefstad S, Provan SA, Kvien TK, Strandén E, Olsen IC, Hisdal J. Carotid plaque characteristics and disease activity in rheumatoid arthritis. *J.Rheumatol.* 2013;40:359–368.
61. Soto Y, Acosta E, Delgado L, Pérez A, Falcón V, Bécquer MA, Fraga Á, Brito V, Álvarez I, Griñán T, Fernández-Marrero Y, López-Requena A, Noa M, Fernández E, Vázquez AM. Antiatherosclerotic Effect of an Antibody That Binds to Extracellular Matrix Glycosaminoglycans. *Arterioscler Thromb Vasc Biol* 2012;32:595–604.
62. Takaoka M, Uemura S, Kawata H, Imagawa K, Takeda Y, Nakatani K, Naya N, Horii M, Yamano S, Miyamoto Y, Yoshimasa Y, Saito Y. Inflammatory response to acute myocardial infarction augments neointimal hyperplasia after vascular injury in a remote artery. *Arterioscler Thromb Vasc Biol* 2006;26:2083–9.
63. Taleb S, Tedgui A, Mallat Z. Adaptive T cell immune responses and atherogenesis. *Curr Opin Pharmacol* 2010;10:197–202.
64. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, Nagai R. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. *Arterioscler Thromb Vasc Biol* 2000;20:2243–7.
65. van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG, Tack CJ. Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. *J Clin Endocrinol Metab* 2011;96:2119–26.

66. van Bussel BC, Schouten F, Henry RM, Schalkwijk CG, de Boer MR, Ferreira I, Smulders YM, Twisk JW, Stehouwer CD. Endothelial dysfunction and low-grade inflammation are associated with greater arterial stiffness over a 6-Year Period. *Hypertens* 2011;58:588–95.
67. van Diepen JA, Berbée JFP, Havekes LM, Rensen PCN. Interactions between inflammation and lipid metabolism: Relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. *Atherosclerosis* 2013;228:306–15.
68. van Zonneveld AJ, de Boer HC, van der Veer EP, Rabelink TJ. Inflammation, vascular injury and repair in rheumatoid arthritis. *Ann Rheum Dis* 2009;69(suppl.1):i57–60.
69. Vuilleumier N, Bratt J, Alizadeh R, Jogestrand T, Hafström I, Frostegård J. Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity. *Scand J Rheumatol* 2010;39:447–53.
70. Wang H., Eitzman D.T. Acute myocardial infarction leads to acceleration of atherosclerosis. *Atherosclerosis* 2013;229:18–22.
71. Whincup PH, Gilg JA, Donald AE, Katterhorn M, Oliver C, Cook DG, Deanfield JE. Arterial distensibility in adolescents: the influence of adiposity, the metabolic syndrome, and classic risk factors. *Circulation* 2005;112:1789–97.
72. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E<sup>-/-</sup> mice. *Am J Pathol* 2000;157:1819–24.
73. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. *J Clin Invest* 1989;84:1086–95.
74. Zambon A, Puato M, Faggini E, Grego F, Rattazzi M, Pauletto P. Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: A flag for non-HDL-C. *Atherosclerosis* 2013;230:106–9.